Otsuka Pharmaceutical and Bristol-Myers Squibb received FDA approval for Abilify® to treat schizophrenia in adolescents between 13 and 17 years. This atypical antipsychotic is reportedly the only available dopamine partial agonist. The drug treats the positive and negative symptoms of the disease, according to the companies.
Otsuka Pharmaceutical discovered Abilify. Along with Bristol-Myers Squibb, the firm has commercializes the drug in the U.S. and major European countries. In November 2002, Abilify was indicated as a schizophrenia therapy in adults.
In November 2002, Abilify was indicated as a schizophrenia therapy in adults. It is also used to treat acute manic or mixed episodes associated with bipolar I disorder in adults.